Product image of Imipenem + Cilastatina Color (Cilastatin, Imipenem Anhydrate) supplied by GNH India

Imipenem + Cilastatina Color

Active Ingredient:
Cilastatin, Imipenem Anhydrate
Origin:
EU

Imipenem + Cilastatina Color (Cilastatin, Imipenem Anhydrate)

Imipenem/cilastatin, the active ingredient in Imipenem + Cilastatina Color, is a carbapenem antibiotic presented as an intravenous solution for injection. It treats severe bacterial infections, including complicated intra‑abdominal, urinary tract, skin and soft‑tissue infections, nosocomial pneumonia, and febrile neutropenia in hospitalized patients. It is indicated for use in adult and pediatric patients when susceptible pathogens are identified.

GNH India supplies Imipenem + Cilastatina Color as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Manufacturer / TM Owner

Color Pharma, Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imipenem/cilastatin is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections.

  • Complicated intra‑abdominal infections: achieves bacterial eradication in the peritoneal cavity and reduces infection‑related morbidity.
  • Complicated urinary tract infections: clears resistant uropathogens and improves renal outcomes.
  • Skin and soft‑tissue infections: provides rapid bacterial clearance in deep tissue infections.
  • Nosocomial pneumonia: penetrates lung tissue to treat hospital‑acquired respiratory infections.
  • Febrile neutropenia: offers broad coverage for Gram‑negative and Gram‑positive organisms in immunocompromised patients.

How It Works

  • Imipenem binds to penicillin‑binding proteins, inhibiting the synthesis of bacterial cell walls and leading to cell lysis. Cilastatin co‑administered inhibits renal dehydropeptidase I, preventing enzymatic degradation of imipenem and thereby increasing its urinary concentrations and overall systemic exposure.

Side Effects

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal discomfort.
  • Diarrhea: may be watery and self‑limiting.
  • Rash: erythematous skin eruption.
  • Headache: transient cranial discomfort.
  • Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects

  • Seizures: especially in patients with renal impairment or CNS disorders.
  • Anaphylaxis: acute hypersensitivity requiring emergency care.
  • Clostridioides difficile infection: severe colitis risk.
  • Stevens‑Johnson syndrome: rare mucocutaneous reaction.
  • Severe neutropenia: marked reduction in white blood cells.

Precautions & Warnings

Use of imipenem/cilastatin requires careful clinical monitoring.

  • Assess renal function: dose adjustment may be needed in renal impairment.
  • Monitor for seizures: avoid in patients with a history of CNS disorders.
  • Evaluate hypersensitivity: discontinue if an allergic reaction occurs.
  • Use caution with concomitant valproic acid: may reduce seizure control.
  • Adjust dose in pediatric patients: follow prescriber guidance.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Imipenem/cilastatin can interact with several medicines.

Major Interactions (Avoid)

  • Valproic acid: carbapenems reduce serum valproate levels, risking breakthrough seizures.
  • Probenecid: may increase imipenem concentrations, heightening toxicity risk.
  • Monoamine oxidase inhibitors: combined use may lower seizure threshold.

Moderate Interactions (Monitor Closely)

  • Diuretics: may exacerbate renal electrolyte disturbances.
  • NSAIDs: concurrent use can affect renal function.
  • Rifampin: may alter imipenem metabolism, requiring monitoring.

Frequently Asked Questions

Imipenem + Cilastatina Color is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft‑tissue infections, hospital‑acquired (nosocomial) pneumonia, and febrile neutropenia in patients with compromised immune systems.

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Cilastatin blocks renal dehydropeptidase I, preventing the breakdown of imipenem in the kidneys and maintaining effective drug concentrations in the urine and bloodstream.

The dose of Imipenem + Cilastatina Color is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function, and local susceptibility patterns. No fixed regimen is provided here.

Imipenem/cilastatin is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but lacking well‑controlled human data. It should be used in pregnancy only if clearly needed, and breastfeeding decisions should be made after weighing potential benefits and risks.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Imipenem/cilastatin offers a broad spectrum of activity against Gram‑negative, Gram‑positive and anaerobic bacteria, similar to meropenem or ertapenem. Its combination with cilastatin protects the drug from renal degradation, potentially providing higher urinary concentrations, which can be advantageous for urinary tract infections.

Store the product at temperatures below 25 °C, in the original packaging, and protect it from moisture and direct light. Do not freeze the solution, and ensure the container remains sealed until use.

The medication is supplied as an intravenous solution for injection. It is administered by a healthcare professional through a vein, typically over a short infusion period, following the dosing instructions provided by the prescriber.

Serious risks include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome.

Patients with a known hypersensitivity to imipenem, cilastatin, or any carbapenem antibiotics should avoid this product. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid without close monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cilastatin, Imipenem Anhydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT